This week's Fierce Biotech is brought to you by NeoGenomics.

How Real-World Data can be used to support a Tumor- Agnostic Era

As precision oncology shifts towards a pan-tumor approach, understanding prevalence rates and testing patterns is crucial for success. Tumor-agnostic trials often miss the diverse clinical implications of treatment efficacy, highlighting the need for real-world data to gain insights across patient subgroups. In this white paper, you will discover:

• The RET testing modality landscape over the last 6 year period
• RET fusion status across 18 different tumor types
• How linking detailed genomic data to medical claims can significantly enhance outcomes in specific patient-populations
• And more